Affordable Access

Oral zinc therapy normalizes serum uric acid level in Wilson's disease patients.

Authors
  • Umeki, S
  • Ohga, R
  • Konishi, Y
  • Yasuda, T
  • Morimoto, K
  • Terao, A
Type
Published Article
Journal
The American Journal of the Medical Sciences
Publisher
Elsevier
Publication Date
Nov 01, 1986
Volume
292
Issue
5
Pages
289–292
Identifiers
PMID: 3777013
Source
Medline
Language
English
License
Unknown

Abstract

The authors investigated changes in the serum uric acid (s-UrA) level seen in a Wilson's disease patient who had to undergo oral zinc therapy because of the occurrence of D-penicillamine-induced acute sensitivity reactions, including neutrophilic agranulocytosis, thrombocytopenia, and skin eruptions. Although s-UrA levels were low before oral zinc therapy (mean +/- SD, 1.60 +/- 0.20), they increased (mean +/- SD, 2.63 +/- 0.32) to within normal range (2.8-8.0 mg/dl) after therapy. There were no significant changes in the renal tubular reabsorption of UrA during oral zinc therapy. This therapy also produced an improvement of the decreased cholinesterase (ChE) values usually seen in Wilson's disease. These results suggest that oral zinc therapy can normalize UrA metabolism in Wilson's disease by improving liver dysfunction and increasing UrA synthesis.

Report this publication

Statistics

Seen <100 times